What are the public health effects of direct-to-consumer drug advertising?
| Autor: | Elizabeth A Almasi, Randall S Stafford, Richard L Kravitz, Peter R Mansfield |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2006 |
| Předmět: | |
| Zdroj: | PLoS Medicine, Vol 3, Iss 3, p e145 (2006) |
| Druh dokumentu: | article |
| ISSN: | 1549-1277 1549-1676 |
| DOI: | 10.1371/journal.pmed.0030145 |
| Popis: | Background to the debateOnly two industrialized countries, the United States and New Zealand, allow direct-to-consumer advertising (DTCA) of prescription medicines, although New Zealand is planning a ban. The challenge for these governments is ensuring that DTCA is more beneficial than harmful. Proponents of DTCA argue that it helps to inform the public about available treatments and stimulates appropriate use of drugs for high-priority illnesses (such as statin use in people with ischemic heart disease). Critics argue that the information in the adverts is often biased and misleading, and that DTCA raises prescribing costs without net evidence of health benefits. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|